Unlike many other advanced biomarkers, CRP and albumin testing are widely available, cost-effective, and can be routinely performed for early risk stratification in NEC, facilitating timely recognition of disease progression, earlier surgical intervention when needed, and, ultimately, improved neonatal outcomes. The gene discussed is ALB; the disease is necrotizing enterocolitis.